Earnings expectations have been reset to a very low level, so the bar for a beat from here is low
Earnings expectations have been reset to a very low level, so the bar for a beat from here is low. The sell-side narrative is split: supporters of the long-term case sit alongside the cautious.
Analyst consensus
- 60-day EPS change (%)
-92.2
- FY2026 EPS consensus
0.04
- FY2026 revenue consensus (bn)
2.91
- Q2 EPS consensus
-0.01
- Q2 revenue consensus (bn)
0.6893
- Q2 revenue growth (YoY)
25-28%
- Source
Zacks
Analyst views
- Rating
Strong Buy
- Source
Seeking Alpha DocShah Financial
- Thesis
Q1 was misunderstood, and the market is punishing transitional losses too harshly. Raised full-year guidance and an unchanged 2030 target mean the long-term case is intact.
- Rating
Buy
- Source
Motley Fool Prosper Junior Bakiny
- Thesis
Could double by 2031. Likes subscriber growth, international expansion and new peptide and Labs categories.
- Note
Q2 guidance is 3-6% above consensus, and the shift to branded drugs is a long-term positive.
- Rating
Hold
- Source
Zacks
Price action
- Change (%)
3.34
- Close
25.05
- Date
2026-05-15
- Note
First green day after four straight declines, a 6.3% rebound from the $23.57 low on 14 May. The cumulative fall since results has narrowed from 14.3% to about 11%. Free cash flow of $53 million and Q2 guidance above consensus may have provided support.
Susquehanna filing
- Detail
The Susquehanna group (G1 Execution Services, SIG Brokerage, Susquehanna Investment Group and Susquehanna Securities) filed a 13G on 15 May. Together they hold 14.5 million shares (6.5%) as at 31 Mar 2026. The position is passive, with shared voting and dispositive power.
- Interpretation
Susquehanna is one of the world's largest options market makers. Positions like this relate to market-making and options hedging and do not signal a directional bullish view. They do show that the HIMS options market has enough liquidity depth to attract top market makers.
Sources 1
- SEC 13G filing (15 May), Seeking Alpha, Motley Fool, Zacks, 15 May closing price data
A brief is a lead for our research, not a verified conclusion or advice.